Skip to main content
. 2020 Sep 14;13(9):245. doi: 10.3390/ph13090245

Figure 2.

Figure 2

Homogeneous ADCs with a drug-to-antibody ratio (DAR) 2 generated through antibody engineering and site-specific bioconjugation.